Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 11/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21854227 | 1.00 | BACE1 (0.50) | BACE1CAPN1ITGB1ITGA4ITGB7 | |
| SCHEMBL20028628 | 0.91 | CAPN1 (0.52) | CAPN1ITGB1ITGA4TRPA1 | |
| SCHEMBL30133690 | 0.91 | CAPN1 (0.52) | CAPN1ITGB1ITGA4TRPA1 | |
| SCHEMBL21854203 | 0.89 | CAPN1 (0.46) | CAPN1ITGB1ITGA4ITGB7TRPA1 | |
| SCHEMBL20027561 | 0.89 | CAPN1 (0.46) | CAPN1ITGB1ITGA4ITGB7TRPA1 | |
| SCHEMBL20027514 | 0.88 | CAPN1 (0.46) | CAPN1ITGB1ITGA4ITGB7TRPA1 | |
| SCHEMBL22897249 | 0.86 | CAPN1 (0.48) | CAPN1TRPA1 | |
| SCHEMBL21854247 | 0.85 | TRPA1 (0.46) | BACE1CAPN1ITGB1ITGA4ITGB7 | |
| SCHEMBL21854249 | 0.85 | TRPA1 (0.46) | BACE1CAPN1ITGB1ITGA4ITGB7 | |
| SCHEMBL22895826 | 0.83 | BACE1 (0.51) | BACE1CAPN1ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | BACE1 465/4885CAPN1 3/4885ITGB1 3429/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | BACE1 465/4885CAPN1 3/4885ITGB1 3429/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | BACE1 254/4885CAPN1 4/4885ITGB1 2849/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | BACE1 465/4885CAPN1 3/4885ITGB1 3429/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | BACE1 465/4885CAPN1 3/4885ITGB1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.